High titre neutralizing antibodies in response to SARS-CoV-2 infection require RBD-specific CD4 T cells that include proliferative memory cells.

Humans CD4-Positive T-Lymphocytes COVID-19 SARS-CoV-2 Antibodies, Neutralizing Epitopes, T-Lymphocyte
CD4 T cells CD4 function SARS-CoV-2 neutralizing antibodies proliferation

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2022
Historique:
received: 31 08 2022
accepted: 31 10 2022
entrez: 22 12 2022
pubmed: 23 12 2022
medline: 24 12 2022
Statut: epublish

Résumé

Long-term immunity to SARS-CoV-2 infection, including neutralizing antibodies and T cell-mediated immunity, is required in a very large majority of the population in order to reduce ongoing disease burden. We have investigated the association between memory CD4 and CD8 T cells and levels of neutralizing antibodies in convalescent COVID-19 subjects. Higher titres of convalescent neutralizing antibodies were associated with significantly higher levels of RBD-specific CD4 T cells, including specific memory cells that proliferated vigorously Our results suggest that targeting CD4 T cell epitopes proximal to and within the RBD-region should be prioritized in booster vaccines.

Sections du résumé

Background
Long-term immunity to SARS-CoV-2 infection, including neutralizing antibodies and T cell-mediated immunity, is required in a very large majority of the population in order to reduce ongoing disease burden.
Methods
We have investigated the association between memory CD4 and CD8 T cells and levels of neutralizing antibodies in convalescent COVID-19 subjects.
Findings
Higher titres of convalescent neutralizing antibodies were associated with significantly higher levels of RBD-specific CD4 T cells, including specific memory cells that proliferated vigorously
Interpretation
Our results suggest that targeting CD4 T cell epitopes proximal to and within the RBD-region should be prioritized in booster vaccines.

Identifiants

DOI: 10.3389/fimmu.2022.1032911 PMID: 36544780 PMC: PMC9762180
pubmed: 36544780
doi: 10.3389/fimmu.2022.1032911
pmc: PMC9762180
doi:

Substances chimiques

Antibodies, Neutralizing 0
Epitopes, T-Lymphocyte 0

Banques de données

ANZCTR
['ACTRN12620000554965']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1032911

Informations de copyright

Copyright © 2022 Phetsouphanh, Khoo, Jackson, Klemm, Howe, Aggarwal, Akerman, Milogiannakis, Stella, Rouet, Schofield, Faulks, Law, Danwilai, Starr, Munier, Christ, Singh, Croucher, Brilot-Turville, Turville, Phan, Dore, Darley, Cunningham, Matthews, Kelleher and Zaunders.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

PLoS Med. 2021 Jul 6;18(7):e1003656
pubmed: 34228725
Cell Mol Immunol. 2021 Oct;18(10):2325-2333
pubmed: 34413488
Immunity. 2021 Sep 14;54(9):2133-2142.e3
pubmed: 34453880
Nat Immunol. 2022 Feb;23(2):210-216
pubmed: 35027728
Blood. 2007 Jul 1;110(1):201-10
pubmed: 17371945
Front Immunol. 2019 Aug 08;10:1844
pubmed: 31440240
Med J Aust. 2021 Apr;214(6):279-280
pubmed: 33657671
Nat Med. 2020 Sep;26(9):1428-1434
pubmed: 32661393
Nat Med. 2003 Sep;9(9):1131-7
pubmed: 12925846
Immunity. 2011 Jan 28;34(1):108-21
pubmed: 21215658
Immunity. 2008 Jun;28(6):847-58
pubmed: 18549802
N Engl J Med. 2022 Mar 31;386(13):1288-1290
pubmed: 35139269
Tuberculosis (Edinb). 2012 Jul;92(4):321-7
pubmed: 22542644
Blood. 2004 Mar 15;103(6):2238-47
pubmed: 14645006
Front Immunol. 2022 Feb 07;13:798300
pubmed: 35197974
MAbs. 2021 Jan-Dec;13(1):1922134
pubmed: 34024246
J Virol. 2022 Apr 27;96(8):e0012822
pubmed: 35343766
Nat Med. 2020 Apr;26(4):453-455
pubmed: 32284614
J Virol. 2006 Oct;80(20):10151-61
pubmed: 17005692
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Front Immunol. 2021 Jun 16;12:708523
pubmed: 34220870
Nat Methods. 2017 Sep;14(9):865-868
pubmed: 28759029
AIDS Res Hum Retroviruses. 2017 Jul;33(7):648-657
pubmed: 28287825
J Immunol. 2002 Jun 1;168(11):5954-8
pubmed: 12023402
Annu Rev Immunol. 2000;18:561-92
pubmed: 10837069
Nat Commun. 2022 Jan 24;13(1):460
pubmed: 35075154
Annu Rev Immunol. 2011;29:621-63
pubmed: 21314428
Immunity. 2021 May 11;54(5):1066-1082.e5
pubmed: 33951417
Cell. 2020 Nov 25;183(5):1340-1353.e16
pubmed: 33096020
Sci Immunol. 2020 Jun 26;5(48):
pubmed: 32591408
Immunity. 2021 May 11;54(5):1055-1065.e5
pubmed: 33945786
Genome Biol. 2019 Dec 23;20(1):296
pubmed: 31870423
PLoS One. 2013 Oct 04;8(10):e74946
pubmed: 24124462
Cell. 2021 Jun 24;184(13):3573-3587.e29
pubmed: 34062119
Nucleic Acids Res. 2020 Jan 8;48(D1):D1057-D1062
pubmed: 31588507
Nat Commun. 2021 Jun 30;12(1):4043
pubmed: 34193870
J Immunol. 2009 Aug 15;183(4):2827-36
pubmed: 19635903
J Virus Erad. 2019 Apr 01;5(2):73-83
pubmed: 31191910
Sci Immunol. 2021 Jan 21;6(55):
pubmed: 33478949
N Engl J Med. 2013 Feb 7;368(6):551-60
pubmed: 23388006
iScience. 2021 Dec 18;25(1):103656
pubmed: 35028536
Eur J Immunol. 2014 Jun;44(6):1644-61
pubmed: 24752698
Front Immunol. 2017 Jan 23;8:19
pubmed: 28167943
Nat Med. 2021 Jan;27(1):78-85
pubmed: 33184509
J Immunol. 1990 Jan 15;144(2):574-82
pubmed: 2104899
Bioinformatics. 2014 Jul 1;30(13):1930-2
pubmed: 24618469
Genome Res. 2009 Sep;19(9):1639-45
pubmed: 19541911
Cell Rep. 2022 Feb 8;38(6):110345
pubmed: 35090598
AIDS. 2020 May 1;34(6):833-848
pubmed: 32044843
Front Immunol. 2018 Apr 09;9:678
pubmed: 29686673
J Med Virol. 2021 Jan;93(1):375-382
pubmed: 32579268
Nature. 2020 Nov;587(7833):270-274
pubmed: 32726801
Science. 2020 Oct 2;370(6512):89-94
pubmed: 32753554
J Virol. 2006 Oct;80(20):10162-72
pubmed: 17005693
PLoS Pathog. 2021 Jul 16;17(7):e1009761
pubmed: 34270631
Genome Biol. 2014 Feb 03;15(2):R29
pubmed: 24485249
Front Immunol. 2013 Apr 24;4:95
pubmed: 23630526
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
F1000Res. 2016 Aug 31;5:2122
pubmed: 27909575
Bioinformatics. 2015 Oct 15;31(20):3356-8
pubmed: 26069265
iScience. 2020 Jun 26;23(6):101212
pubmed: 32512386
Bioinformatics. 2017 Apr 15;33(8):1179-1186
pubmed: 28088763
Nat Rev Immunol. 2020 Oct;20(10):583-584
pubmed: 32908300
Nat Med. 2022 Oct 13;:
pubmed: 36228659
Front Immunol. 2017 Apr 21;8:376
pubmed: 28484447
Lancet. 2021 Mar 27;397(10280):1204-1212
pubmed: 33743221
Nucleic Acids Res. 2013 Jul;41(Web Server issue):W34-40
pubmed: 23671333
Cell. 2019 Jun 13;177(7):1888-1902.e21
pubmed: 31178118
J Exp Med. 1986 Oct 1;164(4):1114-28
pubmed: 2944982
Science. 2021 Jun 18;372(6548):1336-1341
pubmed: 34006597
Nat Chem. 2021 Oct;13(10):963-968
pubmed: 34413500
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Immunity. 2020 Jun 16;52(6):971-977.e3
pubmed: 32413330
Cell Rep Med. 2021 Feb 16;2(2):100204
pubmed: 33521695
Cell Host Microbe. 2021 Jul 14;29(7):1076-1092
pubmed: 34237248
Vaccine. 2016 Oct 17;34(44):5251-5261
pubmed: 27639281
Nature. 1979 Jul 12;280(5718):147-8
pubmed: 317881
Nat Immunol. 2007 Nov;8(11):1246-54
pubmed: 17906628
Nat Microbiol. 2022 Jun;7(6):896-908
pubmed: 35637329
Nat Immunol. 2020 Sep;21(9):1107-1118
pubmed: 32788748

Auteurs

Chansavath Phetsouphanh (C)

Kirby Institute, University of New South Wales (UNSW), Sydney, NSW, Australia.

Weng Hua Khoo (WH)

Garvan Institute of Medical Research, Sydney, NSW, Australia.
St. Vincent's Clinical School, Faculty of Medicine, University of New South Wales (UNSW) Sydney, Sydney, NSW, Australia.

Katherine Jackson (K)

Garvan Institute of Medical Research, Sydney, NSW, Australia.

Vera Klemm (V)

Kirby Institute, University of New South Wales (UNSW), Sydney, NSW, Australia.

Annett Howe (A)

Kirby Institute, University of New South Wales (UNSW), Sydney, NSW, Australia.

Anupriya Aggarwal (A)

Kirby Institute, University of New South Wales (UNSW), Sydney, NSW, Australia.

Anouschka Akerman (A)

Kirby Institute, University of New South Wales (UNSW), Sydney, NSW, Australia.

Vanessa Milogiannakis (V)

Kirby Institute, University of New South Wales (UNSW), Sydney, NSW, Australia.

Alberto Ospina Stella (AO)

Kirby Institute, University of New South Wales (UNSW), Sydney, NSW, Australia.

Romain Rouet (R)

Garvan Institute of Medical Research, Sydney, NSW, Australia.

Peter Schofield (P)

Garvan Institute of Medical Research, Sydney, NSW, Australia.

Megan L Faulks (ML)

Garvan Institute of Medical Research, Sydney, NSW, Australia.

Hannah Law (H)

Kirby Institute, University of New South Wales (UNSW), Sydney, NSW, Australia.

Thidarat Danwilai (T)

NSW State Reference Laboratory for HIV, St. Vincent's Centre for Applied Medical Research, Sydney, NSW, Australia.

Mitchell Starr (M)

NSW State Reference Laboratory for HIV, St. Vincent's Centre for Applied Medical Research, Sydney, NSW, Australia.

C Mee Ling Munier (CML)

Kirby Institute, University of New South Wales (UNSW), Sydney, NSW, Australia.

Daniel Christ (D)

Garvan Institute of Medical Research, Sydney, NSW, Australia.

Mandeep Singh (M)

Garvan Institute of Medical Research, Sydney, NSW, Australia.
St. Vincent's Clinical School, Faculty of Medicine, University of New South Wales (UNSW) Sydney, Sydney, NSW, Australia.

Peter I Croucher (PI)

Garvan Institute of Medical Research, Sydney, NSW, Australia.

Fabienne Brilot-Turville (F)

Brain and Mind Centre, Children's Hospital at Westmead, University of Sydney, Sydney, NSW, Australia.
Sydney Institute for Infectious Diseases, The University of Sydney, Sydney, NSW, Australia.

Stuart Turville (S)

Kirby Institute, University of New South Wales (UNSW), Sydney, NSW, Australia.

Tri Giang Phan (TG)

Garvan Institute of Medical Research, Sydney, NSW, Australia.
St. Vincent's Clinical School, Faculty of Medicine, University of New South Wales (UNSW) Sydney, Sydney, NSW, Australia.

Gregory J Dore (GJ)

Kirby Institute, University of New South Wales (UNSW), Sydney, NSW, Australia.
Department of Infectious Diseases, St. Vincent's Hospital, Sydney, NSW, Australia.

David Darley (D)

Department of Infectious Diseases, St. Vincent's Hospital, Sydney, NSW, Australia.

Philip Cunningham (P)

NSW State Reference Laboratory for HIV, St. Vincent's Centre for Applied Medical Research, Sydney, NSW, Australia.

Gail V Matthews (GV)

Kirby Institute, University of New South Wales (UNSW), Sydney, NSW, Australia.
Department of Infectious Diseases, St. Vincent's Hospital, Sydney, NSW, Australia.

Anthony D Kelleher (AD)

Kirby Institute, University of New South Wales (UNSW), Sydney, NSW, Australia.
Department of Immunology, St Vincent's Hospital, Sydney, NSW, Australia.

John J Zaunders (JJ)

NSW State Reference Laboratory for HIV, St. Vincent's Centre for Applied Medical Research, Sydney, NSW, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › High titre neutralizing antibodies in response...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Lymphocytes T CD4+ › High titre neutralizing antibodies in response...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › COVID-19 › High titre neutralizing antibodies in response...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Nidovirales › Coronaviridae › Coronavirus › Betacoronavirus › Virus du SRAS › SARS-CoV-2 › High titre neutralizing antibodies in response...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps neutralisants › High titre neutralizing antibodies in response...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Épitopes › Déterminants antigéniques des lymphocytes T › High titre neutralizing antibodies in response...